During the last months of the coronavirus pandemic, with all those public restrictions and health interventions, the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears now to have been raised in some countries around the world. Iran was one of those first countries facing the second wave of coronavirus, due to the lack of appropriate public restrictions because of economic problems the country is facing. The clinical and demographic characteristics of severe cases and non-severe cases of Coronavirus Disease (COVID-19) in 192 patients in Tehran, Iran, between June 16 and July 11, 2020, were investigated. The patients were divided into severe cases (n = 82) and non-severe cases (n = 110). Demographic and clinical characteristics were compared between the two study clusters. The mean age was 54.6 ± 17.2 years, and the most common presenting symptom was persistent cough (81.8%) and fever (79.7%). The logistic regression model revealed that age, BMI, and affected family members were statistically associated with severity. Patients with complicated conditions of disorders faced more hospitalization days and medical care than the average statistical data. As the coronavirus spike in the case and death reports from June 2020, we observed the rise in the incidence of severe cases, where 42.7% (82/192) of cases have resulted in severe conditions. Our findings also suggested that the effect of IFB (Betamethasone) was more valid than the other alternative drugs such as LPV/r and IVIg.

Background: One of the bitter experiences is acute postoperative pain. The severity of this pain has been reported as moderate to severe in 21% of patients. Materials and methods: In this controlled randomized clinical trial, 106 consecutive patients under elective abdominal surgery in Bouali Hospital were enrolled and randomly assigned to receive alprazolam or placebo the night before surgery. The pain severity was determined by visual analog scale (VAS) and compared between the groups at three intervals, including recovery time, and 4 hours and 24 hours after surgery. Results: The mean age (P=0.55) and gender (P=0.78) of patients were similar between the two groups. 24hour analgesic dose (meperidine) was significantly lower in patients that received alprazolam (25±0 mg) compared to placebo group (35.53±12.68) (P=0.002). The pain severity in VAS was 7.70±1.84, 4.96±1.56 and 3.06±1.35 cm in alprazolam group, and 7.55±1.44, 5.70 ± 1.19 and 3.94 ± 1.13 cm in the placebo group, in recovery time, and 4 hours and 24 hours after surgery respectively. The results in this study revealed that there was statistically significant difference at first 24 hours after surgery (P=0.038) but were no statistically significant differences between two groups for the postoperative pain in recovery and in first 4 hours (P > 0.05). Also Conclusion: The results in this study revealed that there was statistically significant difference at the first 24 hours after surgery (P=0.038), but were no statistically significant differences between two groups for the postoperative pain in recovery and in first 4 hours (P>0.05). Also 24-hour analgesic dose (meperidine) was significantly lower in patients that received alprazolam (P=0.002).